GlaxoSmithKline PLC (GSK.LN) and Nasdaq-listed Innoviva Inc. (INVA) Wednesday announced they have received positive data from a study for their treatment for patients with chronic obstructive pulmonary disease.
FTSE 100-listed GSK said that the eight-week study of 236 patients with the disease compared a once-daily long-acting muscarinic antagonist, called Anoro Ellipta, and a long-acting beta agonist fixed-dose combination, Stiolto Respimat.
Continue Reading Below
Innoviva Chief Executive Michael Aguiar said the data demonstrated the benefit of Anoro Ellipta versus Stiolto Respimat for patients with chronic obstructive pulmonary disease whose primary therapeutic need is additional bronchodilatation, the dilation of airways in the lungs.
Shares in GSK were up 4.50 pence, or 0.3%, to 1,362 pence at 1115 GMT.
Write to Maryam Cockar at email@example.com
(END) Dow Jones Newswires
November 01, 2017 07:50 ET (11:50 GMT)